...
ovid-img

Ovid Therapeutics Inc, Common Stock

OVID

NSQ

$1.064

+$0

(0%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$75.27M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
104.09K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.41
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.68 L
$4.1 H
$1.064

About Ovid Therapeutics Inc, Common Stock

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameOVIDSectorS&P500
1-Week Return-7.02%-3.39%0.2%
1-Month Return1.92%-1.92%2.72%
3-Month Return-5.36%-10.54%7.31%
6-Month Return34.25%-4.47%10.44%
1-Year Return-68.55%4.06%27.53%
3-Year Return-67.38%0.94%30.88%
5-Year Return-76.18%36.67%89.21%
10-Year Return-91.35%102.87%199.95%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue-12.62M208.38M1.50M391.69K[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":6.05,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":0.72,"profit":true},{"date":"2023-12-31","value":0.19,"profit":true}]
Cost of Revenue255.00K--1.38M1.60M[{"date":"2019-12-31","value":15.97,"profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":86.54,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit(255.00K)12.62M208.38M1.50M391.69K[{"date":"2019-12-31","value":-0.12,"profit":false},{"date":"2020-12-31","value":6.05,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":0.72,"profit":true},{"date":"2023-12-31","value":0.19,"profit":true}]
Gross Margin(Infinity%)100.00%100.00%100.00%100.00%[{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Expenses61.41M94.05M84.17M57.05M59.67M[{"date":"2019-12-31","value":65.3,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":89.5,"profit":true},{"date":"2022-12-31","value":60.66,"profit":true},{"date":"2023-12-31","value":63.45,"profit":true}]
Operating Income(61.41M)(81.43M)124.21M(55.55M)(59.28M)[{"date":"2019-12-31","value":-49.44,"profit":false},{"date":"2020-12-31","value":-65.56,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-44.72,"profit":false},{"date":"2023-12-31","value":-47.73,"profit":false}]
Total Non-Operating Income/Expense1.90M---11.84M[{"date":"2019-12-31","value":16.01,"profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(60.46M)(81.04M)124.16M(54.17M)(52.34M)[{"date":"2019-12-31","value":-48.69,"profit":false},{"date":"2020-12-31","value":-65.27,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-43.63,"profit":false},{"date":"2023-12-31","value":-42.15,"profit":false}]
Income Taxes(1.20M)(306.85K)1.33M(2.76M)5.00[{"date":"2019-12-31","value":-90.55,"profit":false},{"date":"2020-12-31","value":-23.09,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-207.76,"profit":false},{"date":"2023-12-31","value":"-","profit":true}]
Income After Taxes(59.26M)---(52.34M)[{"date":"2019-12-31","value":-5925801700,"profit":false},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":-5233896400,"profit":false}]
Income From Continuous Operations(60.46M)(81.04M)122.83M(54.17M)(48.52M)[{"date":"2019-12-31","value":-49.22,"profit":false},{"date":"2020-12-31","value":-65.97,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-44.1,"profit":false},{"date":"2023-12-31","value":-39.5,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(59.26M)(80.73M)122.83M(51.41M)(52.34M)[{"date":"2019-12-31","value":-48.24,"profit":false},{"date":"2020-12-31","value":-65.72,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-41.85,"profit":false},{"date":"2023-12-31","value":-42.61,"profit":false}]
EPS (Diluted)(1.58)(1.40)2.03(0.77)(0.75)[{"date":"2019-12-31","value":-77.83,"profit":false},{"date":"2020-12-31","value":-68.97,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-37.93,"profit":false},{"date":"2023-12-31","value":-36.95,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

OVID
Cash Ratio 5.39
Current Ratio 5.66

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

OVID
ROA (LTM) -36.04%
ROE (LTM) -36.61%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

OVID
Debt Ratio Lower is generally better. Negative is bad. 0.26
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.74

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

OVID
Trailing PE NM
Forward PE 1.79
P/S (TTM) 119.16
P/B 0.99
Price/FCF NM
EV/R 43.74
EV/Ebitda NM
PEG NM

FAQs

What is Ovid Therapeutics Inc share price today?

Ovid Therapeutics Inc (OVID) share price today is $1.064

Can Indians buy Ovid Therapeutics Inc shares?

Yes, Indians can buy shares of Ovid Therapeutics Inc (OVID) on Vested. To buy Ovid Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in OVID stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Ovid Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Ovid Therapeutics Inc (OVID) via the Vested app. You can start investing in Ovid Therapeutics Inc (OVID) with a minimum investment of $1.

How to invest in Ovid Therapeutics Inc shares from India?

You can invest in shares of Ovid Therapeutics Inc (OVID) via Vested in three simple steps:

  • Click on Sign Up or Invest in OVID stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Ovid Therapeutics Inc shares
What is Ovid Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Ovid Therapeutics Inc (OVID) is $4.1. The 52-week low price of Ovid Therapeutics Inc (OVID) is $0.68.

What is Ovid Therapeutics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Ovid Therapeutics Inc (OVID) is

What is Ovid Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Ovid Therapeutics Inc (OVID) is 0.99

What is Ovid Therapeutics Inc dividend yield?

The dividend yield of Ovid Therapeutics Inc (OVID) is 0.00%

What is the Market Cap of Ovid Therapeutics Inc?

The market capitalization of Ovid Therapeutics Inc (OVID) is $75.27M

What is Ovid Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Ovid Therapeutics Inc is OVID

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top